Terns Pharmaceuticals (TERN, Financial) is making significant progress in 2025 with its key clinical projects. The company successfully concluded the dose escalation phase of its TERN-701 Phase 1 study for chronic myeloid leukemia (CML) in under a year. Excitingly, Terns has now commenced the dose expansion phase of this study.
Moreover, the rapid patient enrollment in the Phase 2 FALCON trial for TERN-601 targeting obesity underscores a strong interest from both patients and clinical researchers. This interest centers around the unique characteristics of the oral small molecule GLP1-RA. Terns is on schedule to reveal critical data from these studies in the latter part of the year and reports a solid financial position, with cash reserves expected to last until 2028.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Terns Pharmaceuticals Inc (TERN, Financial) is $19.79 with a high estimate of $34.00 and a low estimate of $7.50. The average target implies an upside of 559.52% from the current price of $3.00. More detailed estimate data can be found on the Terns Pharmaceuticals Inc (TERN) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Terns Pharmaceuticals Inc's (TERN, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
